VPT:CC - Ventripoint Diagnostics Announces Dr. Alvira Macanovic as President and CEO
(TheNewswire)
Toronto, Ontario – The Newswire –January 2, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Corporation "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce the appointment of Dr.Alvira Macanovic as President and CEO of the Corporation effectiveJanuary 1, 2023. Dr. George Adams will continue asExecutive-Chairman of the Corporation with responsibilities for newapplications, investor relations and strategic partnerships.
“In 2022 Ventripoint has transitioned from adevelopment company to a fully operating and commercialization companywith a worldwide customer base and it is now time for an operationalCEO to drive the Corporation forward,” stated Dr. George Adams,Executive-Chairman. “I will be focusing on strategic issues andgovernance for the Corporation.”
"It has been my great pleasure to work with theVentripoint team, stated Dr. Alvira Macanovic,President and CEO. “ I look forward toleading the company through this next phase and continuing our missionto improve the lives of heart patients worldwide."
Dr. Macanovic has had increasing responsibilitieswithin the Corporation since her appointment as Manager of RegulatoryAffairs & Quality Assurance in 2017. She has been instrumental inbuilding the current cohesive teams for manufacturing, sales andmarketing, development, quality assurance, and regulatory affairs asthe Vice-President of Operations, as well as effectively engaging thecardiology community and driving strategic partnerships.
She has over 15 years of experience in pharmaceuticaland medical device related industries where she has worked withresearchers, start-ups, SMEs, and multi-national companies tocommercialize medical products. Previously, Dr. Macanovic worked foran organization supported through the Centers of Excellence forCommercialization and Research in various leadership roles, includingbusiness development, sales, and commercialization strategy thecommercialization of medical imaging technologies. She obtained aBachelor of Science in Biochemistry from McGill University and a PhDin Chemistry from Concordia University.
The Board of Directors has granted Dr. Macanovic250,000 options at an exercise price of $.30 with a lifespan of 10years and vesting equally over three years.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile andcan be used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.